Oncorus is developing potent oncolytic immunotherapies for malignant and benign tumors


Robust Viral Potency

γ34.5 retained for WT replication & IDO inhibition

gB:NT mutation to enhance target cell entry


Superior Efficacy

MULTIPLE IMMUNE-MODULATORY PAYLOADS

Large 25kb capacity enables integration of multiple payloads capable of recruiting all arms of the immune system.

Tumor Matrix Modification

Matrix metalloproteinases degrade the extracellular matrix and facilitate viral spread, enhancing efficacy.

 


SUPERIOR SAFETY

MIR CONTROLLED REPLICATION & PAYLOAD EXPRESSION

Engineering of miR-T cassettes into critical replication genes allows robust replication in tumor tissues; arming genes expressed in tumor only, increasing potency & limiting toxicity.

Targeted Viral Entry

Retargeted glycoproteins enables selective uptake by cells expressing tumor antigens.